Linden Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Linden Advisors’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22,746	Closed	-$132K	–	382
2023 Q2	$132K	Hold	22,746	–	–	﹤0.01%	245
2023 Q1	$860K	Hold	22,746	–	–	0.01%	249
2022 Q4	$678K	Hold	22,746	–	–	0.01%	326
2022 Q3	$760K	Hold	22,746	–	–	0.01%	389
2022 Q2	$910K	Hold	22,746	–	–	0.01%	412
2022 Q1	$1.2M	Buy	22,746 +8,534	+60%	+$429K	0.01%	474
2021 Q4	$787K	Hold	14,212	–	–	﹤0.01%	508
2021 Q3	$1.1M	Hold	14,212	–	–	0.01%	419
2021 Q2	$1.84M	Hold	14,212	–	–	0.01%	446
2021 Q1	$2.34M	Hold	14,212	–	–	0.02%	429
2020 Q4	$3.33M	Hold	14,212	–	–	0.02%	280
2020 Q3	$1.47M	Hold	14,212	–	–	0.02%	229
2020 Q2	$557K	Hold	14,212	–	–	0.01%	209
2020 Q1	$475K	Hold	14,212	–	–	0.01%	180
2019 Q4	$665K	Hold	14,212	–	–	0.01%	186
2019 Q3	$1.27M	Hold	14,212	–	–	0.02%	154
2019 Q2	$1.93M	Hold	14,212	–	–	0.03%	144
2019 Q1	$3.89M	Hold	14,212	–	–	0.09%	103
2018 Q4	$1.79M	Hold	14,212	–	–	0.05%	106
2018 Q3	$5.83M	Hold	14,212	–	–	0.18%	80
2018 Q2	$7.67M	Hold	14,212	–	–	0.24%	75
2018 Q1	$5.88M	Buy	+14,212	New	+$7.75M	0.14%	99

Other funds holding TCON

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Linden Advisors's TCON Position: Q3 2023 in Review

Linden Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2023, closing a stake of 22,746 shares — an estimated $132K sold.

Linden Advisors first reported a position in TCON in Q1 2018 and held it in 22 quarters. The position peaked at $7.67M in Q2 2018. 21 funds tracked by Wall St. Rank hold TCON as of Q3 2023.

Linden Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Linden Advisors sold 22,746 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $132K.
Linden Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 22 quarters.
Linden Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $7.67M in Q2 2018.
21 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Linden Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.